Logo image of GENT.OL

GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Fundamental Analysis

OSL:GENT - Euronext Oslo - NO0010748866 - Common Stock - Currency: NOK

58  -0.4 (-0.68%)

Fundamental Rating

6

Taking everything into account, GENT scores 6 out of 10 in our fundamental rating. GENT was compared to 58 industry peers in the Health Care Equipment & Supplies industry. GENT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GENT is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

GENT had positive earnings in the past year.
GENT had a positive operating cash flow in the past year.
GENT had negative earnings in 4 of the past 5 years.
In multiple years GENT reported negative operating cash flow during the last 5 years.
GENT.OL Yearly Net Income VS EBIT VS OCF VS FCFGENT.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

GENT's Return On Assets of 19.72% is amongst the best of the industry. GENT outperforms 96.55% of its industry peers.
The Return On Equity of GENT (23.34%) is better than 87.93% of its industry peers.
GENT has a Return On Invested Capital of 6.07%. This is in the better half of the industry: GENT outperforms 62.07% of its industry peers.
Industry RankSector Rank
ROA 19.72%
ROE 23.34%
ROIC 6.07%
ROA(3y)0.42%
ROA(5y)-3.57%
ROE(3y)0.25%
ROE(5y)-4.48%
ROIC(3y)N/A
ROIC(5y)N/A
GENT.OL Yearly ROA, ROE, ROICGENT.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

With an excellent Profit Margin value of 29.78%, GENT belongs to the best of the industry, outperforming 94.83% of the companies in the same industry.
GENT's Operating Margin of 10.34% is in line compared to the rest of the industry. GENT outperforms 58.62% of its industry peers.
GENT has a Gross Margin (54.46%) which is in line with its industry peers.
GENT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.34%
PM (TTM) 29.78%
GM 54.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.26%
GM growth 5Y-7.11%
GENT.OL Yearly Profit, Operating, Gross MarginsGENT.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GENT is destroying value.
GENT has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for GENT remains at a similar level compared to 5 years ago.
GENT has a better debt/assets ratio than last year.
GENT.OL Yearly Shares OutstandingGENT.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
GENT.OL Yearly Total Debt VS Total AssetsGENT.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 16.00 indicates that GENT is not in any danger for bankruptcy at the moment.
GENT has a Altman-Z score of 16.00. This is amongst the best in the industry. GENT outperforms 100.00% of its industry peers.
The Debt to FCF ratio of GENT is 2.20, which is a good value as it means it would take GENT, 2.20 years of fcf income to pay off all of its debts.
GENT has a better Debt to FCF ratio (2.20) than 82.76% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that GENT is not too dependend on debt financing.
The Debt to Equity ratio of GENT (0.03) is better than 96.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 2.2
Altman-Z 16
ROIC/WACC0.72
WACC8.48%
GENT.OL Yearly LT Debt VS Equity VS FCFGENT.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

GENT has a Current Ratio of 5.38. This indicates that GENT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.38, GENT belongs to the top of the industry, outperforming 98.28% of the companies in the same industry.
A Quick Ratio of 3.85 indicates that GENT has no problem at all paying its short term obligations.
The Quick ratio of GENT (3.85) is better than 93.10% of its industry peers.
Industry RankSector Rank
Current Ratio 5.38
Quick Ratio 3.85
GENT.OL Yearly Current Assets VS Current LiabilitesGENT.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

8

3. Growth

3.1 Past

GENT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 522.84%, which is quite impressive.
GENT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.52%.
The Revenue has been growing by 25.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)522.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%422.94%
Revenue 1Y (TTM)12.52%
Revenue growth 3Y22.3%
Revenue growth 5Y25.96%
Sales Q2Q%13.73%

3.2 Future

The Earnings Per Share is expected to grow by 58.89% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 31.72% on average over the next years. This is a very strong growth
EPS Next Y76.24%
EPS Next 2Y58.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year31.13%
Revenue Next 2Y31.72%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GENT.OL Yearly Revenue VS EstimatesGENT.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M 250M
GENT.OL Yearly EPS VS EstimatesGENT.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 0 1 -1 2 -2

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 20.07 indicates a rather expensive valuation of GENT.
Based on the Price/Earnings ratio, GENT is valued a bit cheaper than 79.31% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.25. GENT is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 31.95 indicates a quite expensive valuation of GENT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GENT is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of GENT to the average of the S&P500 Index (22.15), we can say GENT is valued slightly more expensively.
Industry RankSector Rank
PE 20.07
Fwd PE 31.95
GENT.OL Price Earnings VS Forward Price EarningsGENT.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GENT is on the same level as its industry peers.
GENT's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 356.75
EV/EBITDA 33.27
GENT.OL Per share dataGENT.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

GENT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as GENT's earnings are expected to grow with 58.89% in the coming years.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y58.89%
EPS Next 3YN/A

1

5. Dividend

5.1 Amount

GENT has a yearly dividend return of 0.71%, which is pretty low.
GENT's Dividend Yield is comparable with the industry average which is at 2.19.
Compared to an average S&P500 Dividend Yield of 2.40, GENT's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.71%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DP0%
EPS Next 2Y58.89%
EPS Next 3YN/A
GENT.OL Yearly Income VS Free CF VS DividendGENT.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

GENTIAN DIAGNOSTICS ASA

OSL:GENT (5/30/2025, 7:00:00 PM)

58

-0.4 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners30.99%
Inst Owner ChangeN/A
Ins Owners2.59%
Ins Owner ChangeN/A
Market Cap894.36M
Analysts85.71
Price Target68.34 (17.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.71%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.49%
Revenue NY rev (3m)-1.49%
Valuation
Industry RankSector Rank
PE 20.07
Fwd PE 31.95
P/S 5.88
P/FCF 356.75
P/OCF 66.46
P/B 4.61
P/tB 5.4
EV/EBITDA 33.27
EPS(TTM)2.89
EY4.98%
EPS(NY)1.82
Fwd EY3.13%
FCF(TTM)0.16
FCFY0.28%
OCF(TTM)0.87
OCFY1.5%
SpS9.86
BVpS12.58
TBVpS10.74
PEG (NY)0.26
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 19.72%
ROE 23.34%
ROCE 7.88%
ROIC 6.07%
ROICexc 10.54%
ROICexgc 14.02%
OM 10.34%
PM (TTM) 29.78%
GM 54.46%
FCFM 1.65%
ROA(3y)0.42%
ROA(5y)-3.57%
ROE(3y)0.25%
ROE(5y)-4.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.26%
GM growth 5Y-7.11%
F-Score5
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 2.2
Debt/EBITDA 0.22
Cap/Depr 122.17%
Cap/Sales 7.2%
Interest Coverage 250
Cash Conversion 54.51%
Profit Quality 5.54%
Current Ratio 5.38
Quick Ratio 3.85
Altman-Z 16
F-Score5
WACC8.48%
ROIC/WACC0.72
Cap/Depr(3y)104.09%
Cap/Depr(5y)116.83%
Cap/Sales(3y)8.32%
Cap/Sales(5y)10.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)522.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%422.94%
EPS Next Y76.24%
EPS Next 2Y58.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.52%
Revenue growth 3Y22.3%
Revenue growth 5Y25.96%
Sales Q2Q%13.73%
Revenue Next Year31.13%
Revenue Next 2Y31.72%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y318.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year215.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-77.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.94%
OCF growth 3YN/A
OCF growth 5YN/A